Concerned about patient safety, the American Medical Association (AMA) is urging the Trump administration to abandon its plan to make certain unapproved peptides more widely available for human use.
In a letter (PDF) to the Department of Health and Human Services (HHS), the AMA opposed the “rushed” decision to permit the compounding of certain peptides because they have not been approved for safe use by the Food and Drug Administration (FDA).
“We should not bypass the science and put patients at risk by making them guinea pigs for unapproved drugs,” said AMA President Willie Underwood III, MD, MSc, MPH. “If these substances are safe and effective, the evidence should demonstrate that through the FDA’s rigorous review process.”
Peptides are small pieces of protein that occur naturally in the body and help control functions such as growth, healing and appetite. Unproven peptides may pose serious health risks, including allergic reactions, infections, hormonal imbalances and other unexpected side effects, according to the FDA website.
Under the proposed policy, HHS would allow the compounding of BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon, none of which have received FDA approval. The AMA warned that allowing these substances, which are popular in wellness circles, to become more widely available could expose patients to products with unknown identity, purity, potency, dosing and safety.
The AMA noted that the FDA previously excluded these substances from the 503A Bulks List and none are currently under review as part of an active Investigational New Drug application. If finalized, the HHS policy would effectively endorse the use of non-FDA-approved substances for injection without providing patients assurance of their safety, efficacy or quality.
The AMA urged HHS to rescind the policy and require the substances’ safety and efficacy to undergo the full FDA review process, including well-designed clinical trials, before marketing or clinical use. “Just because a pharmacy can compound these peptides does not mean that consumers can or should trust the safety of such compounded substances,” the AMA said in its letter.
At its recent Interim Meeting, AMA delegates adopted a policy calling on HHS and others to immediately rescind policies that ease restrictions on compounding and distributing synthetic peptides that lack FDA approval.
The entire letter can be found here (PDF).
Media Contact
About the American Medical Association
The American Medical Association is the physicians’ powerful ally in patient care. As the only medical association that convenes 190+ state and specialty medical societies and other critical stakeholders, the AMA represents physicians with a unified voice to all key players in health care. The AMA leverages its strength by removing the obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises and, driving the future of medicine to tackle the biggest challenges in health care.